Laventatug Biosimilar Antibody-Drug Conjugate (LIV-1) for Research

Cat No.: GMP-Bios-INN-1253

Anti-SLC39A6/ZIP6 therapeutic antibody (Pre-made Laventatug biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Laventatug (development code BRY-812) is a humanized monoclonal antibody-drug conjugate targeting SLC39A6 (LIV-1/ZIP6) conjugated to monomethylauristatin E (MMAE). It is developed for solid tumors. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1253-1mg 1mg 4635
GMP-Bios-INN-1253-10mg 10mg
GMP-Bios-INN-1253-100mg 100mg
GMP-Bios-INN-1253-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Laventatug biosimilar, Whole mAb ADC, Anti-SLC39A6/ZIP6 Antibody: Anti-LIV-1/ZIP6/SLC39A6/Zinc transporter ZIP6 therapeutic antibody
INN Name Laventatug
Target SLC39A6/ZIP6
Format Whole mAb ADC
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC